Fed’s Jackson Hole Speech Helps Fuel Stellar Weekly Bull Market Gains – $IWM $IWC $XBI Jump!

By John F. Heerdink, Jr.

“We cannot solve our problems with the same thinking we used when we created them.” – Albert Einstein

Happy Saturday All!

I hope that you had a great week investing in the markets and otherwise during this late week in the summer. Thank you again for your attention and I look forward to speaking to each and everyone of you soon.

As for the markets, they were overall bullish in nature this week where we realized a significant bounce back from last week’s negative performances. A number of headlines helped create the bullish disposition including the realization that a number of marquis names beat Wall Street’s earnings expectations and further issued upward guidance i.e. Dow 30 component Salesforce (CRM) where CEO Marc Benioff was bold enough to state, “I don’t think the delta variant will be material to our business. If anything, it only accelerates it.” The House also pushed forward a $3.5T budget resolution & a $1T infrastructure bill. There was also a report that even suggested that we might be reaching a peak of sorts regarding the spread of the Delta virus coupled with the confirmation that the FDA awarded a full approval to Pfizer (PFE) & BioNTech’s (BNTX) COVID-19 vaccine for all that are 16 years and older.

At the end of the week, we achieved several record highs as the S&P 500 closed at 4,509.37 (+1.5%) & is now up 20.1% YTD ranking as the 5th largest annual price gain over the last 20 years. Note that we have now seen more than 50 record closes year-to-date. The Dow 30 closed at 35,455.80 (+1%) & now is up 15.8% YTD, & the Nasdaq closed at 15,129.50 (+2.8%) & is up 17.4% YTD. The small caps on the Russell 2000 jumped to close at 2,277.15 (+5.1%) after last week’s sizable 2.5% decline and now are up 15.3% YTD. The MicroCaps jumped as the iShares Micro-Cap ETF (IWC) closed at $148.74 hopping +6.65% after last weeks 3.03% decline & is now up a stellar 25.36% YTD.

However, when we look at sector performances for the week, it was not all rosy, as there were five of the 11 sectors that ended in the red. The utilities fell 2.1%, the consumer staples sector fell 1.4%, the health care sector dropped 1.2%, & real estate ticked down .3%, which are all generally considered ‘defensive’ sectors by nature. The energy sector bounced back significantly jumping 7.3% to lead all sectors as the growth trade was on and oil prices closed at $68.73, +10.6% for the week, and is now up 41.7% YTD. Not to be a downer, but I wonder if the spreading of the Delta Variant spread will soon dampen investors spirits and the world’s growth prospects sometime soon.

MACRO REPORTS – JACKSON HOLE – YIELDS

On Friday, Fed’s Chair Jerome Powell delivered his stout defense of the central bank’s monetary policy via his speech during the annual Jackson Hole Summit that was once again held virtually because of the pandemic. In case you missed it, I recommend that you view his speech now my visiting this video link. In quick summary, he stayed consistent with his delivery and the monetary position exuding confidence that the Fed would be considering tapering asset purchases sooner than later, but this would not mean that they would be raising interest rates when if they tapered. He further noted that jobs are recovering, but have further to go, & that inflation is high, but the Fed still feels confident that it is temporary.

Many more macroeconomic reports surfaced again this week. On Monday, the macroeconomic schedule delivered the existing home sales report which confirmed a 2% month/month rise in July to a seasonally adjusted annual rate of 5.99M , while total sales in July moved up 1.5% over a year ago. The preliminary IHS Markit Manufacturing PMI report confirmed a drop to 61.2 in August, while the preliminary IHS Markit Services PMI report showed a drop to 55.2 in August. On Tuesday, the new home sales report confirmed a 1% rise m/m in July to a seasonally adjusted annual rate of 708k, while new home sales were off 27.2% year over year. On Wednesday, the total durable goods orders report confirmed a move down by .1% m/m in July, while orders, excluding transportation, rose .7%. On a Y/Y basis, durable goods orders have moved up 25.3% & orders, excluding transportation, are up 17.7%. On Thursday, the second estimate report for Q2 GDP came in at 6.6% as expected & the GDP Deflator came in at 6.1% basically inline as well. The Initial claims report for the week ending August 21 confirmed a rise by 4k to 353k as continuing claims for the week ending August 14 moved lower by 3k to 2.862M. On Friday, the Personal income report confirmed a 1.1% move up m/m in July. The Personal spending report showed a edge higher by .3%, however real PCE moved lower by.1% while the PCE Price Index moved by .4%. The core PCE Price Index moved up .3%. The final University of Michigan Consumer Sentiment Index report for August came in basically inline with the preliminary reading at 70.3, but significantly lower that July’s 81.2. The Advance report for International Trade in Goods report for July confirmed a deficit of $86.4b, while the Advance report for Retail Inventories for July moved up .4% & the Advance report for Wholesale Inventories for July rose .6%.

The yield curve moved higher this week, but faded on Friday after the Fed’s speech. The 10-yr yield ended up 5 basis points wk/wk to close at 1.31%, while the 2-yr moved up 1 basis point wk/wk closing at .22%. The U.S. Dollar Index moved lower from 93.45 to close at 92.68.

Next week, the macroeconomic schedule will serve the Pending Home Sales report for July, the Consumer Confidence report, the Hourly Earnings report, & the Unit Labor Costs report.

STORIES YOU MAY HAVE MISSED

App Developers Apparently Not Going To Be Appeased By Apple’s ‘Empty Gestures’

Verizon Issues Green Bond Impact Report Confirms Full Allocation Of $1B

Salesforce Q2 Earnings Beat Estimates – Raises Full-Year Guidance

Disney’s Cruise Line Issues Mandatory Vaccination Proof For Florida To Bahamas Trips

Walmart’s Launches Walmart GoLocal A ‘New Delivery As A Service’ Business Diversifying Its Revenue Streams

Yikes!..Supply Chain Issues Yank Milkshakes From British McDonald’s Menu

FAANG’s OVERALL STRONG

The FAANG’s weekly returns were as follows: Apple (AAPL) closed at $148.60, +.28%, Amazon (AMZN) closed at $3,349.63, +4.68% for the week, Alphabet (GOOG) closed at $2,891.01, +4.42% for the week, Facebook (FB) closed at $372.63, +3.69% this week & Netflix (NFLX) closed at $558.92/share, +2.20%. The MicroSectors FANG+ Index 3X Leveraged ETN (FNGU), which offers 3x leveraged exposure to an index of “FANG” companies, and other companies that exhibit similar characteristics, closed at $36.51, +12.44% for the week.

EV- TECH – NVDA NEW RECORD

Leading EV car maker Tesla (TSLA) moved higher to close at $711.92, +4.65% as Tesla’s boss CEO Elon Musk announced they are seeking to build a humanoid robot called ‘Tesla Bot’. The announcement was made as part of AI Day, a series of tech talks hosted by Tesla in California to recruit machine learning talent. Musk revealed that in the time to come, the human-robot has the chance to transform the world economy by lowering labor costs.

One to watch and if you need another reason to own some Amazon, Rivian Automotive announced a IPO filing on Friday as Goldman Sachs, JPMorgan and Morgan Stanley are the underwriters and could seek a $70B valuation. In July, the company closed a $2.5B funding round led by Amazon, Ford Motor & T. Rowe Price & has previously raised an amazing $10.5B since 2019. Oh, and Amazon has agreed to purchase 100k Rivian electric vans already. Nothing like putting your money where you mouth is….

Shares of Ford Motor Co. (F) closed at $13.31, +5.89% for the week.

Microsoft (MSFT) closed at $299.72, +1.52% for the week after recently recording a new record high of $305.84.

Chip making giant NVIDIA Corporation closed $226.36, +8.74% for the week and establishing a new record high of $227.22. Taiwan Semi (TSM) confirmed that it is planning to raise prices of their more advanced chips with a range of 10-20% next year. the chip shortage still persists to some degree folks.

Cathie Wood’s ARK Innovation ETF (ARKK) closed at $122.03, +5.38% for the week.

The Technology Select Sector SPDR Fund (XLK) closed at $158, +1.45% for the week.

DISNEY

Disney (DIS closed at $180.14, +2.87% for the week. Recently, DIS reported a better than expected Q3 earnings report. Disney’s streaming users growth (Disney+) blasted through expectations checking in with 116M vs. the 113.1M. People cannot seem to do without their Star Wars and Marvel related content…Revenues also came in at $17.02B vs. $16.8B expected & $11.78B Y/Y & adjusted earnings per share were $.80 vs. $.55 expected & $.08 Y/Y. Shares of Disney jumped in the aftermarkets to $189.38, +5.63%.

BIOTECH BROADLY REBOUNDS – $XBI JUMPS

The Nasdaq Biotechnology ETF (IBB) closed at $171.81, +2.78% for the week, & is up 13.41% this year. The NYSE ARCA Biotech Index (^BTK) closed at 5,939.27, +2.88% for the week and is up +3.49% YTD. In concert this week, the SPDR S&P Biotech ETF (XBI) closed at $132.03, jumping a whopping 8.11% but is still off 6.22% for the year. The XBI’s 52-wk range is $100.64-$174.79.

GOLD & SILVER REVERSES COUSRE

Reversing the 2 week downward trend, Gold prices rebounded to close at $1,819, up $37 from the $1,782 close last week & silver prices closed sharply higher at $24.07/oz., up $1.04 from the $23.03/oz. close last Friday. Hecla Mining Company (NYSE: HL) closed $6.07, +9.96% for the week.

MEMES REPORT

AMC Entertainment (AMC), closed at $40.84, +18.691% for the week & GameStop (GME) closed at $204.95, +28.66% for the week. “Short sellers alone aren’t enough to contain the bulls,” stated Jim Cramer during his Mad Money Recap recently. What do you think?

Virgin Galactic Holdings (SPCE) closed at $26.05, +6.2% this week as the space race rages on and it looks as though we found the proverbial floor after the recent run to $62.80 and the subsequent selloff.

Infamous ‘meme brokerage’ firm Robinhood Markets, Inc., (HOOD) moved higher this week closing at $46.87, +9.92% for the week.

Seanergy Maritime Holdings Corp. (SHIP) closed at $1.26, +17.76% for the week. The ‘only pure-play Capesize ship-owner publicly listed in the US’, announced recently that its Board of Directors has authorized a share repurchase plan. Under the Plan, the Company may repurchase up to $17 million of its outstanding common shares, representing approximately 10% of the Company’s market capitalization as of August 10, 2021. Capsize rates continue to surge which should bold for them!

Bitcoin

Bitcoin $BTC.X moved +2.74% higher again this week eclipsing the $49k level now at $49,012.86.

NEXT WEEK

The markets will enjoy another normal 5-day trading week during the 3rd week of August.

VP WATCHLIST UPDATES

Please review our complete VP Watchlist that includes Apple (AAPL), Disney (DIS), Tesla (TSLA) & a select group of emerging names. The pages will allow you to learn more and keep up with these companies daily.

For now, see the summaries or five of the emerging companies from the VP Watchlist below:

Shares of INmune Bio, Inc. (NASDAQ: INMB) moved significantly higher over the week closing at $20.03, +21.17%. The 52-wk range is $7.28 – $29.99.

- After the market closed Thursday, Aug. 25th, INmune Bio announced that the first patient who received INKmune™ as a potential treatment for high-risk myelodysplastic syndrome (MDS) has successfully shown the NK activation and functional differentiation predicted by previously published in vitro experiments.NK cells need multiple activating signals to progress from a resting state to the triggering of cytolysis and cytokine secretion. INmune Bio has studied these pathways extensively and demonstrated that binding of NK cells with INKmune™ provides multiple activating signals and drives resting NK to the phenotype of memory-like NK (mlNK) cells with enhanced cancer-killing function. The company believes that this is the first ever successful generation of mlNK cells in patients.INMB Shares have traded over $20 in the aftermarkets.

- On Wednesday, Aug. 4th, INmune Bio, Inc. reported its financial results for the second quarter ended June 30, 2021 and provided a business update. Raymond J Tesi, M.D., CEO/CMO of INmuneBio (INMB) stated, “We continue our planning and setup for a Phase 2 clinical trial of our lead candidate, XPRO™ (Xpro1595™), in patients with mild Alzheimer’s disease, which we plan to initiate by year-end. We have already demonstrated that XPRO™ can reduce neuroinflammation and decreases biomarkers of neurodegeneration and improve synaptic function. If successful in Phase 2, we believe XPRO™ has the potential to be among the most significant advancements in the treatment of Alzheimer’s Disease (AD) and other neurodegenerative diseases in many years. At the Alzheimer’s Association International Conference last week, we introduced a new biomarker – Apparent Fiber Density (AFD), a measure of axonal integrity measured by MRI. XPRO™ increases AFD in patients receiving 1mg/kg/week. We believe the novel non-invasive white matter analytics of white matter free water and apparent fiber density will be very useful in the development of XPRO™ in AD, Treatment Resistant Depression (TRD) and the many other CNS indications we hope to attack in the future. Last month, we treated the first patient in the first Phase 1 clinical trial of our NK cell priming platform, INKmune, in high-risk myelodysplastic syndrome (MDS). We are calling INKmune a pseudokine because, in vitro, it converts the resting NK cells into memory-like NK cells that can kill cancer cells as well or better than NK cells treated cytokines such as IL-12, IL-15 and IL-18 alone or in combination.”

- On July 26th, INmune Bio announced the design of its upcoming Phase 2 clinical trial of XProTM in patients diagnosed with mild Alzheimer’s disease (AD) at AAIC. The announcement was accompanied by the release of additional biomarker data from the Phase 1b AD trial that shows improvement in white matter (myelinated axons) that degenerate in AD patients. READ MORE.

- On July 22, LUMICKS, a leading next generation life science tools company renowned for its innovative platforms for Dynamic Single-Molecule and Cell Avidity analysis, announced that it has installed its ground-breaking z-Movi® Cell Avidity Analyzer at INmune Bi0. INmune Bio is employing the z-Movi cell avidity analysis platform to demonstrate that the mechanism of action of the tumor-priming is the increase in NK cell:tumor cell avidity. Early data acquired by the z-Movi support their hypothesis that increased cell avidity enhances NK cell killing of tumor cells. This allows screening of batches of INKmune for potency and provides a potential biomarker of in vivo activity by measuring the tumor avidity of NK cells isolated from patients before and after INKmune treatment.

- On July 14th, INmune Bio announced that it has entered into a definitive agreement with one healthcare focused institutional investor and one family office for the purchase and sale of 1,818,182 shares of its common stock at a price of $22 per share for gross proceeds of approximately $40 million in a registered direct offering. The closing of the offering is expected to occur on or about July 16, 2021, subject to the satisfaction of customary closing conditions. A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering. INmune Bio intends to use the net proceeds from this offering for working capital and general corporate purposes and to advance the development of its product candidates and expand its pipeline. This includes the completion and data readout from the Company’s planned Phase 2 clinical trial of its lead clinical candidate, XPro1595, in patients suffering from Alzheimer’s disease, which is expected to commence by the end of 2021. “With this investment, we expect the Company’s Phase II program in Alzheimer’s disease is completely funded” said RJ Tesi MD, CEO of Inmune Bio.

- On July 12th, INmune Bio, Inc. announced that the first patient has been treated in the company’s Phase 1 clinical trial of its Natural Killer (NK) cell priming platform, INKmune, as a potential treatment for high-risk myelodysplastic syndrome (MDS). This Phase 1 open label study will enroll nine patients with a confirmed diagnosis of MDS with excess blasts in a 3×3 dose escalation protocol. The primary endpoint is the safety and tolerability of INKmune when administered intravenously. Most secondary endpoints are biomarkers and include the change in percentage of blasts in peripheral blood and bone marrow, the change in autologous NK cell activity and functional maturity into tumor-induced memory-like NK cells in vivo. The overall response rate using WHO criteria, and duration of response will also be reported. READ MORE.

- On July 7th, The Maxim Group’s analyst raised his price target from $32 to $42 today.

- On June 14th, INMB announced that it had entered into a new $15M credit facility with Silicon Valley Bank (SVB) and an affiliate of SVB Financial Group. INmune intends to use the proceeds from the facility to partially fund the buyout of an option held by Xencor, Inc.(XNCR), resulting from INmune’s in-licensing of XPro1595 (now known by its generic name, pegipanermin) in October 2017. XPro1595 is a next-generation inhibitor of tumor necrosis factor (TNF) that uses a dominant-negativeTNF technology that is very different from approved TNF inhibitors that block the effects of both soluble and trans-membrane TNF. Pegipanermin neutralizes soluble TNF, without affecting trans-membrane TNF or TNF receptors. XPro1595 could have substantial beneficial effects in patients with Alzheimer’s and other neurodegenerative diseases by decreasing neuroinflammation. Total consideration to be paid to Xencor by INmune is $18.3 million, comprised of $15 million of cash and $3.3 million of INMB shares at a price of $17.14 resulting in the issuance of 192,533 shares. Pursuant to the original 2017 in-licensing agreement, INmune granted Xencor an option to purchase an additional number of shares of common stock equal to 10% of INmune’s fully diluted company shares for a period of seven years. The retirement of the Xencor option eliminates an estimated 2.1 million shares of potential future common stock dilution upon exercise of the option.

- On June 2nd, the United States Adopted Name Council (USAN) has adopted the name “Pegipanermin” for INMB’s lead clinical candidate, XPro1595.

- On May 18th, I hosted Immune Bio’s CEO RJ Tesi at the Tribe Public Presentation & Q&A Event for a fascinating discussion and his presentation titled “Advancing Treatment To Repair Our Aging Innate Immune System to Fight Alzheimer’s.” Please view the event video here.

InMed Pharmaceuticals, Inc. (NASDAQ: INM) is leading clinical-stage pharmaceutical company developing cannabinoid-based drug candidates for high unmet medical needs and IntegraSyn, a proprietary and cost effective manufacturing approach for synthesized rare cannabinoids. Please visit the INM page at our website to learn more and check out the videos section too.

Shares of InMed closed trading this week at $2.44, +17.31% for the week. The 52-wk range is $2.05 -$8.94.

- Eric. A. Adams, President and CEO of INM, and Dr. Eric Hsu, Senior Vice President of Pre-Clinical Research & Development, will present at H.C. Wainwright Ophthalmology Virtual Conference on Tuesday, August 17, 2021. Mr. Adams and Dr. Hsu will provide an overview of InMed’s ocular program including INM-088, a topical eye drop formulation under development for the treatment of glaucoma. The active pharmaceutical ingredient (“API”) in INM-088 is cannabinol, also known as CBN, a rare cannabinoid showing promise in its potential to provide neuroprotection and to reduce intraocular pressure of the eye.
- On July 9th, Roth Capital Partners analyst Scott Henry, CFA issued an update report with. BUY Rating titled, “INM: Favorable Take on BayMedica LOI” that includes a $11.50 12-Month Price Target.
- On July 2, InMed announced that it had closed the previously announced private placement and after deducting the placement agent fees and estimated offering expenses payable by the Company, the Company received net proceeds of approximately US$11 million. H.C. Wainwright & Co. acted as the exclusive placement agent for the private placement. Under the terms of the private placement, an aggregate of 4,036,327 common shares (or common share equivalents in lieu thereof) and warrants to purchase up to an aggregate of 4,036,327 common shares were purchased, at an effective purchase price of US$2.973 per common share (or common stock equivalent in lieu thereof) and associated warrant. The warrants have an exercise price of US$2.848 per share, are exercisable immediately and have a term of five years. InMed intends to use the net proceeds from the offering to continue pipeline development, advance business development activities and for general working capital purposes.
- On June 29th, INM announced that it has entered into a non-binding letter of intent (the “LOI”) to acquire BayMedica Inc. (“BayMedica”), a private company based in Nevada and California that specializes in the manufacture and commercialization of rare cannabinoids. BayMedica is a revenue-stage biotechnology company leveraging its significant expertise in synthetic biology and pharmaceutical chemistry to develop efﬁcient, scalable, and proprietary manufacturing approaches to produce high quality, regulatory-compliant rare cannabinoids for consumer applications. BayMedica is currently commercializing the rare cannabinoid CBC (cannabichromene) as a B2B supplier to distributors and manufacturers marketing products in the health and wellness sector. BayMedica is currently planning additional rare cannabinoid launches for the coming year. In addition to their manufacturing and commercial activities in the health and wellness arena, BayMedica is researching cannabinoid analogs as potential drug candidates for pharmaceutical purposes. Those BayMedica proprietary compounds are based upon the structures of naturally-occurring cannabinoids and are designed to either augment the potential therapeutic effect against specific diseases or enhance product safety, or both.
- On Thursday, June 17th, InMed Pharmaceuticals (NASDAQ: INM) announced that its continued optimization of IntegraSyn™ has increased the cannabinoid yield to a level of 5 g/L, further improving the economics of this proprietary manufacturing approach in advance of large-scale production. InMed’s cannabinoid yield of 5 g/L significantly exceeds currently reported industry yields. The Company has continued to make important steps to further optimize the IntegraSyn™ manufacturing process, resulting in the improved yield of 5 g/L, surpassing InMed’s previously reported yield levels of 2 g/L, an already commercially viable yield. The impact of improved yield is a significant reduction in the overall cost of manufacturing due to greater amount of cannabinoid produced per batch. InMed is now focused on manufacturing scale-up to larger batch sizes in the second half of calendar year 2021. “We are very excited by these impressive yield levels that further validates the IntegraSyn™ manufacturing approach as a commercially viable solution for large-scale, pharmaceutical-grade GMP production of rare cannabinoids. While we continue to refine the process, we are now focused on advancing the program towards the next key milestones, including the manufacture of our first large-scale batch through a GMP-ready process in the coming months. We continue to believe InMed’s proprietary IntegraSyn™ approach will be one of the most important manufacturing processes for pharma-grade cannabinoids,” stated Eric A. Adams, President and Chief Executive Officer of InMed.

Shares of Natural-Killer cell (NKcell) focused biopharmaceutical firm Fate Therapeutics (FATE) closed at $72.64, +8.4% for the week. The 52-wk high is $121.16.

- After the close on Thursday Aug. 20th, FATE highlighted positive interim clinical data from the Company’s FT516 and FT596 programs for patients with relapsed / refractory B-cell lymphoma. FT516 is the Company’s universal, off-the-shelf natural killer (NK) cell product candidate derived from a clonal master induced pluripotent stem cell (iPSC) line engineered with a novel high-affinity, non-cleavable CD16 (hnCD16) Fc receptor, which is designed to maximize antibody-dependent cellular cytotoxicity (ADCC), a potent anti-tumor mechanism by which NK cells recognize, bind and kill antibody-coated cancer cells. The Company’s FT596 program incorporates both the hnCD16 Fc receptor and a chimeric antigen receptor (CAR) targeting CD19, which is designed to enable multi-antigen targeting of tumor cells, as well as an IL-15 receptor fusion (IL-15RF) to enhance NK cell activity and survival.

- August 4th, Fate reported business highlights and financial results for the second quarter ended June 30, 2021. Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics stated, “We are very pleased with the early clinical safety and activity we have observed with our off-the-shelf, iPSC-derived NK cell programs in relapsed / refractory lymphoma and acute myeloid leukemia, where interim Phase 1 data indicate FT516 and FT538 are well tolerated and can deliver complete responses for patients. We look forward to sharing additional clinical data from our FT516 and FT596 programs in B-cell lymphoma at our upcoming investor event. Additionally, treatment of the first patient with FT819, the first-ever iPSC-derived T-cell therapy to undergo clinical investigation, is a landmark achievement and further demonstrates the Company’s leadership in off-the-shelf, iPSC-derived cell therapy and the versatility of its proprietary iPSC Product Platform.”

- On Aug. 2 Fate announced that the first patient has been treated with FT819, an off-the-shelf chimeric antigen receptor (CAR) T-cell therapy targeting CD19+ malignancies. FT819 is the first-ever CAR T-cell therapy derived from a clonal master induced pluripotent stem cell (iPSC) line, a renewable cell source that enables mass production of high quality, allogeneic CAR T cells with greater product consistency, off-the-shelf availability, and broader patient accessibility. FT819 is engineered with several first-of-kind features designed to improve the safety and efficacy of CAR T-cell therapy.

Shares of Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, closed at closed at $3.73, +14.42% for the week.

- On Aug 13th, Atossa announced financial results for the fiscal quarter ended June 30, 2021, and provided an update on recent company developments. “We continue to experience encouraging progress in our MBD and COVID-19 programs, with new regulatory approvals being granted in Sweden for a Phase 2 trial in MBD and authorization in Australia to commence a Phase 2 study of AT-H201 for respiratory illness associated with COVID-19. In the meantime, we continue to enjoy a strong balance sheet, which we have significantly expanded over the last three quarters and will facilitate our development plans over the near term. As we actively explore the possibility for strategic expansion into other areas where we might see near-term milestones and results, we also urge all of our shareholders to exercise their right to vote at our special stockholder’s meeting on September 7, 2021. We urge a vote in favor of the proposal to increase authorized shares, which will provide the Company with the flexibility to issue shares as part of these potential acquisitions, collaborations and partnerships, a common strategy successful biotech companies seeking to grow shareholder value employ in order to create a more attractive opportunity for all. We look forward to continuing to update our stockholders on these opportunities as they develop,” stated Dr. Steven Quay, Atossa’s President and Chief Executive Officer.

- On July 29th, Atossa filed a proxy inviting shareholders to attend the Special Meeting of Stockholders of Atossa Therapeutics, Inc., which will be held virtually on September 7, 2021, at 9:00 a.m. Eastern time. This Special Meeting will be held in a virtual meeting format only. You can virtually attend the live webcast of the Special Meeting at http://www.viewproxy.com/AtossaTherapeutics/2021/SM. Only stockholders of record who held common stock at the close of business on the record date, July 29, 2021 (the “Record Date”), may attend virtually and vote virtually at the Special Meeting, including any adjournment or postponement thereof. At the Special Meeting, you will be asked to consider and vote upon approval of an amendment to the certificate of incorporation to increase the number of shares of authorized common stock by 100,000,000 shares. No other items of business are expected to be considered at the meeting, pursuant to the Company’s Bylaws. The enclosed Proxy Statement more fully describes the details of the business to be conducted at the Special Meeting. After careful consideration, our Board of Directors has unanimously approved the proposal and recommends that you vote FOR the proposal. After reading the Proxy Statement, please mark, date, and sign and return the enclosed proxy card in the accompanying reply envelope to ensure receipt by our tabulator. YOUR SHARES CANNOT BE VOTED UNLESS YOU SIGN, DATE AND RETURN THE ENCLOSED PROXY OR ATTEND THE SPECIAL MEETING VIRTUALLY. Stockholders of record on the record date may also vote on-line or by phone by following the instructions contained in the accompanying Proxy Statement.

Shares of INVO Bioscience, Inc. (INVO), a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell®, the world’s only in vivo Intravaginal Culture System, closed at $3.85.

- On August 16th, INVO announced their financial and operating results for the second quarter ended June 30, 2021 and provided a business update. Steve Shum , CEO of INVO stated. “Our team made excellent progress during the second quarter of 2021 toward our key objectives, headlined by last week’s official opening of our first INVO Center practice in Birmingham, AlabamaWe feel INVO is now well positioned for success based on the following core foundational elements developed over the past 2 years. We believe there is a substantial underserved patient population with infertility challenges and a real need to expand access to treatment. In our opinion, this is a multi-billion-dollar market expansion opportunity, and INVOcell is well positioned to address the unmet medical need.”

- On Aug.2, INVO announced the Company’s first Joint Venture INVO Center practice in the United States, based in Birmingham, Alabama, will officially open on August 9, 2021. Dr. Hammond commented, “With the opening of the country’s first INVOcell medical practice, we are advancing a core mission towards improving access to advanced fertility services for the many patients who would otherwise never have the opportunity. To date, we have already received numerous advanced inquiries via word of mouth and have dozens of patients scheduled for initial patient consultations who are eager to proceed with treatment. As we officially open the center next week, we expect to accelerate our marketing programs with the help of the INVO marketing team to enhance overall patient awareness around Innovative Fertility Specialists, An INVO Center.”

- On July 14th, INVO announced the appointment of world renowned women’s health expert, Dr. Barbara Levy, M.D., FACOG, FACS as the Company’s Senior VP, Global Clinical Integration to accelerate affordable infertility treatment INVOcell’s Global OB/GYN Clinical Integration Strategy. Dr. Levy is considered one of the most influential clinical executives in the world, recently serving as Vice President, Health Policy at the American College of Obstetricians and Gynecologists (ACOG) and chair of the American Medical Association/Specialty Society Relative Value Scale Update Committee. She joins INVO Bioscience to help further develop and accelerate the Company’s global OB/GYN channel strategy. Steve Shum, CEO of INVO Bioscience, said, “We are excited to have Dr. Levy join the INVO team to support our mission to bring care to the vast underserved patient population around the world experiencing infertility challenges. She has a clear understanding of the role that OB/GYNs can play in helping to democratize fertility care on a global basis by providing accessibility to affordable and effective treatments, the key hallmarks of the INVOcell technology. We look forward to leveraging her experience, relationships, and influence to accelerate our OB/GYN clinical implementation strategy in the years to come.”

- On June 30th, VP Watchlist company, INVO Bioscience, Inc. (NASDAQ: INVO) expanded their North American footprint as they announced on June 30th that they had signed a joint venture agreement in partnership with reproductive specialist Dr. Sue Ellen Carpenter, M.D. through its wholly-owned subsidiary, INVO Centers, LLC, to open an INVO clinic in Atlanta. The clinic, Bloom Fertility, is scheduled to open in the second half of 2021. INVO Bioscience will provide funding for start-up and operating costs and own 40% of the Atlanta Joint Venture. Dr. Sue Ellen Carpenter, MD, is Board Certified in Obstetrics and Gynecology. With over 30 years of experience in reproductive medicine, Dr. Carpenter’s specialties include in vitro fertilization, treating congenital anomalies associated with infertility, as well as endometriosis and polycystic ovarian syndrome. Noted for excellence in her field and a “Top Doctor, Atlanta 2019 and 2020″ she delivers lectures across the country and has published more than a dozen papers on reproduction and fertility. She is an active member of the American Society of Reproductive Medicine (ASRM) as well as the Georgia OB GYN Society. Note that INVO Bioscience has also signed clinic partnerships in Birmingham, Alabama and the San Francisco Bay area earlier this year, along with its Mexico partnership in late 2020, which is scheduled to open later this year. These clinics, through the utilization of the INVOcell technology, in addition to the multiple clinic and distribution partnerships throughout the world are bringing advanced fertility care and much needed expanded access to the millions of underserved people.

- On June 15th, INVO Bioscience, Inc. (NASDAQ: INVO), announced further foundational progress as they appointed of Andrea Goren as the Company’s Chief Financial Officer. In a career approaching 27 years, Mr. Goren has extensive experience in numerous financial functions, including service as a public company CFO, company director, capital raising activities as well as mergers and acquisition experience. Mr. Goren has served as managing director and CFO of Phoenix Group, a New York City-based private equity firm specializing in micro-cap and nano-cap public companies. He served as vice president of Shamrock Group, the Roy Disney family private investment firm in London; and was a director at New York City-based Madison Capital Group, a corporate advisory firm focused on U.S. / European Union cross border transactions. Mr. Goren holds a Bachelor of Arts degree from Connecticut College in New London, Connecticut, and an MBA from the Columbia Business School in New York City.

- On May 17, INVO announced financial results for the first quarter of 2021 ended March 31, 2021 and provides a business update. Steve Shum, Chief Executive Officer of INVO Bioscience stated, “This was an exciting start to the year 2021 for INVO Bioscience as we advanced our INVO Clinic strategy with the signing of our first U.S.-based INVOcell exclusive facility in Birmingham, Alabama, the signing of a partnership agreement to establish and operate a center in Northern California, and the completion of our product registration in Mexico. We expect these initial centers to become operational in the second half of the year. Throughout this year, we have expanded our real-world experience data and positive results with INVOcell, enhanced our online training tools, materials, and capabilities and have experienced a substantial increase in active training sessions for our international partners and distributors. We believe the combination of strong commercialization partnerships and company-owned clinics, both in the U.S. and around the world, is key to expanding INVOcell’s adoption within the fertility industry. In addition to the progress made executing new commercialization agreements, we have strengthened our marketing capabilities to support the INVOcell-only centers and our growing number of distribution partners. Meryle Lynn Chamberlain, a tenured women’s health and fertility solution marketing professional, joined us as Director of Marketing in March 2021, while Rebecca Messina, current Senior Advisor at McKinsey & Co. and former Global Chief Marketing Officer at both Uber and Beam Suntory joined our board of directors in April 2021. As we look to increase access to care and expand fertility treatment across the globe, our market positioning and overall strategies are more important than ever. The addition of Meryle Lynn and Rebecca will enhance our ability to successfully accomplish these goals. As we look to the remainder of 2021, we have set a number of key objectives, including the opening of our first company-owned clinics in Mexico and the United States. Additionally, we will seek to build our international revenues this year through our growing list of international distribution partners as they finish training, and we complete local product registration requirements. Of note, we are extremely pleased to see the initial INVO procedures performed recently in Spain and Malaysia, which reflects the groundwork done by our team in these specific markets, which we believe will help in further expanding the overall awareness of the potential outside of the U.S. Finally, we are continuing to advance our 5-day label expansion efforts with the FDA in the U.S. market with a goal of completing this effort in 2021. It remains our belief that there is strong global demand for fertility services and INVOcell is well-positioned through our growing, global footprint to play a key role in helping to turn the dream of creating a family for millions of people around the world into a reality through our accessible, efficient, and affordable fertility treatment.”

- On May 11, a 13G was filed that confirms that David Sable’s (a former #IVF doc turned portfolio manager) Special Situations Fund of AWM Investment Company increased their ownership to 11.1% or 1,154,153 share ownership of INVO Bioscience (INVO). They held 625k/6.5% as of the 13G filing 2-12-2021. If you are not familiar with them, I believe if you do a relatively small amount sleuthing you will find out that they are one of the most successful multi-billion funds over the last 20-years, especially in finding small undiscovered microchips. I believe that they led the round of $13M at $3.20 a share in November 12, 2020 that pushed INVO uplist to the NASDAQ. Here’s the 13G filing. The company only has 10,424,229 shares issued and outstanding as of March 31, 2021.

- Industry forecasts suggest that only 1% to 2% of the estimated 150 million infertile couples worldwide are currently being treated. INVO’s mission is to increase access to care and expand infertility treatment across the globe with a goal of improving patient affordability and industry capacity. Since January 2019, INVO Bioscience has signed commercialization agreements in the United States, India, as well as parts of Africa and Eurasia and Mexico for the INVOcell device.

Thanks again for your attention this week. Please continue to share your thoughts, questions, & ideas as we move forward.

In the meantime, please enjoy the balance of the weekly newsletter’s videos, quotes, updates.

Investing & Inspiration

“We cannot solve our problems with the same thinking we used when we created them.” – Albert Einstein
“When you’re an investor, you can look at the quantitative and qualitative elements of an investment, but there’s a third aspect: What you feel in your gut.” – Kevin O’Leary
“Set your course by the stars, not by the lights of every passing ship.” – Omar N. Bradley
“Do not take life too seriously. You will never get out of it alive.” – Elbert Hubbard
“Education is not only a ladder of opportunity, but it is also an investment in our future.” – Ed Markey
“Every good painter paints what he is.” – Jackson Pollock
If you believe in yourself and have dedication and pride – and never quit, you’ll be a winner. The price of victory is high but so are the rewards.” – Bear Bryant
“Your mindset matters. It affects everything – from the business and investment decisions you make, to the way you raise your children, to your stress levels and overall well-being.” – Peter Diamandis
“You cannot have a positive life and a negative mind.” – Joyce Meyer
“Like wildebeest and zebra migration across the Serengeti, investment managers and consultants, too, have a habit of running together and, every now and then, changing direction.” – Sanjaya Baru
“If people are anything but enthusiastic about the information or ideas that they’re sharing, they’re either not that invested in what they’re doing – or they’re not communicating that investment effectively.” – Ana Kasparian
“Life consists not in holding good cards but in playing those you hold well.” – Josh Billings
“Friend, there’s no greater investment in life than in being a people builder. Relationships are more important than our accomplishments.” – Joel Osteen
“It’s only natural that the heavy users help contribute to the investment to keep the Web healthy. That is the most important concept of net neutrality.” – Lowell McAdam
“The more sand that has escaped from the hourglass of our life, the clearer we should see through it.” – Jean Paul
“Eliminate emotion from your investment program.” -John C. Bogle
“Modern medical advances have helped millions of people live longer, healthier lives. We owe these improvements to decades of investment in medical research.” – Ike Skelton
“In every investment, before I get involved or invest, I always see what the mindset of the founder, the CEO, is.” – Zaza Pachulia
“An investment said to have an 80% chance of success sounds far more attractive than one with a 20% chance of failure. The mind can’t easily recognize that they are the same.” – Daniel Kahneman
“The return on investment in global health is tremendous, and the biggest bang for the buck comes from vaccines. Vaccines are among the most successful and cost-effective health investments in history.” – Seth Berkley
“Few things in the world are more powerful than a positive push. A smile. A world of optimism and hope. A ‘you can do it’ when things are tough.” – Richard M. DeVos
To be yourself in a world that is constantly trying to make you something else is the greatest accomplishment.” – Ralph Waldo Emerson
“We all have dreams. But in order to make dreams come into reality, it takes an awful lot of determination, dedication, self-discipline, and effort.” – Jesse Owens
“The pessimist complains about the wind; the optimist expects it to change; the realist adjusts the sails.” – William Arthur Ward- American Writer, Born 1921
“Once you replace negative thoughts with positive ones, you’ll start having positive results.” – Willie Nelson
“The secret of your future is hidden in your daily routine.” – Mike Murdock
“Work hard for what you want because it won’t come to you without a fight. You have to be strong and courageous and know that you can do anything you put your mind to. If somebody puts you down or criticizes you, just keep on believing in yourself and turn it into something positive.” – Leah LaBelle
“Opportunity is missed by most people because it is dressed in overalls and looks like work”. -Thomas A. Edison
“Education is not only a ladder of opportunity, but it is also an investment in our future.” – Ed Markey
“Human behavior flows from three main sources: desire, emotion, and knowledge.” – Plato
“We are what our thoughts have made us; so take care about what you think. Words are secondary. Thoughts live; they travel far.” – Swami Vivekananda
“Success is not final, failure is not fatal: it is the courage to continue that counts.” – Winston Churchill
“If you don’t know where you are going, any road will get you there.” – Lewis Carroll
“Don’t worry about being a star, worry about doing good work, and all that will come to you.” – Ice Cube
“It is not in the stars to hold our destiny but in ourselves.” – William Shakespeare
“Prediction is very difficult, especially if it’s about the future.” – Niels Bohr
“It is indeed true that the stock market can forecast the business cycle.” -Paul Samuelson
“The wisest rule in investment is: when others are selling, buy. When others are buying, sell. Usually, of course, we do the opposite. When everyone else is buying, we assume they know something we don’t, so we buy. Then people start selling, panic sets in, and we sell too.” – Jonathan Sacks
“What lies behind you and what lies in front of you, pales in comparison to what lies inside of you.” – Ralph Waldo Emerson
“Each new generation born is in effect an invasion of civilization by little barbarians, who must be civilized before it is too late.” – Thomas Sowell
“Life is 10% what happens to you and 90% how you react to it.” – Charles R. Swindoll
“The truth is you don’t know what is going to happen tomorrow. Life is a crazy ride, and nothing is guaranteed.” – Eminem
“View health as an investment, not an expense.” – John Quelch
“Opportunity does not knock, it presents itself when you beat down the door.” – Kyle Chandler
“If you don’t know where you are going, any road will get you there.” – Lewis Carroll
“Once you replace negative thoughts with positive ones, you’ll start having positive results.” – Willie Nelson
“That which does not kill us makes us stronger.” – Friedrich Nietzsche
“Nothing in life is to be feared, it is only to be understood. Now is the time to understand more, so that we may fear less.” – Marie Curie
“A problem is a chance for you to do your best.”– Duke Ellington
“The best way to predict the future is to create it.” -Peter Drucker
“I’m involved in the stock market, which is fun and, sometimes, very painful.” – Regis Philbin
“Who owns the future? This is the question at the heart of every stock market.” – John Landgraf
“One of the funny things about the stock market is that every time one person buys, another sells, and both think they are astute.” – William Feather
“While I’m sure some millennials are concerned with the ethical issues involved in mining for diamonds, the main reason they steer clear of the gems is because, well, they’re a dumb investment.” – Ana Kasparian
“The wisest rule in investment is: when others are selling, buy. When others are buying, sell. Usually, of course, we do the opposite. When everyone else is buying, we assume they know something we don’t, so we buy. Then people start selling, panic sets in, and we sell too.” – Jonathan Sacks
“We must shift our thinking away from short-term gain toward long-term investment and sustainability, and always have the next generations in mind with every decision we make.” – Deb Haaland
“The only way to have a friend is to be one.” – Ralph Waldo Emerson
“If you believe in yourself and have dedication and pride – and never quit, you’ll be a winner. The price of victory is high but so are the rewards.” – Bear Bryant
“Investing in women’s lives is an investment in sustainable development, in human rights, in future generations – and consequently in our own long-term national interests.” -Liya Kebede
“Success is not final, failure is not fatal: it is the courage to continue that counts.” – Winston Churchill
“Our greatest glory is not in never falling, but in rising every time we fall.” – Confucius
“Give me a lever long enough and a fulcrum on which to place it, and I shall move the world.” – Archimedes
“Who controls the past controls the future. Who controls the present controls the past.” – George Orwell
“If you get up in the morning and think the future is going to be better, it is a bright day. Otherwise, it’s not.” – Elon Musk
“The pessimist complains about the wind; the optimist expects it to change; the realist adjusts the sails.” – William Arthur Ward
“Start where you are. Use what you have. Do what you can.” – Arthur Ashe
“Netflix, Amazon, iTunes – whatever platforms emerge – we are looking at as having the same potential that home video had for the movie business. Which means there are entirely new opportunities to monetize our capital investment in content and do so in ways that work for distributors, for consumers and for creators.” – Bob Iger
“When you have no one to answer to, vendetta as investment strategy is as legitimate as anything.” – Carl Icahn
“No other investment yields as great a return as the investment in education. An educated workforce is the foundation of every community and the future of every economy.” – Brad Henry
“In my view, the biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital. Not only is the mere drop in stock prices not risk, but it is an opportunity. Where else do you look for cheap stocks?” – Li Lu
“Modern medical advances have helped millions of people live longer, healthier lives. We owe these improvements to decades of investment in medical research.”– Ike Skelton
“Stock market goes up or down, and you can’t adjust your portfolio based on the whims of the market, so you have to have a strategy in a position and stay true to that strategy and not pay attention to noise that could surround any particular investment.” – John Paulson
“Your mindset matters. It affects everything – from the business and investment decisions you make, to the way you raise your children, to your stress levels and overall well-being.” – Peter Diamandis
“Inflation destroys savings, impedes planning, and discourages investment. That means less productivity and a lower standard of living.” – Kevin Brady
“Cash – in savings accounts, short-term CDs or money market deposits – is great for an emergency fund. But to fulfill a long-term investment goal like funding your retirement, consider buying stocks. The more distant your financial target, the longer inflation will gnaw at the purchasing power of your money.” – Suze Orman
“Bitcoin, in the short or even long term, may turn out be a good investment in the same way that anything that is rare can be considered valuable. Like baseball cards. Or a Picasso.” – Andrew Ross Sorkin
“I think you have to learn that there’s a company behind every stock and there’s only one real reason why stocks go up. Companies go from doing poorly to doing well or small companies grow to large companies.” – Peter Lynch
“Historically, there has been a bull market in the commodities every 20 or 30 years.” – Jim Rogers
“The markets generally are unpredictable, so that one has to have different scenarios. The idea that you can actually predict what’s going to happen contradicts my way of looking at the market.” – George Soros
“Stop trying to predict the direction of the stock market, the economy or the elections.” – Warren Buffett
“An important key to investing is to remember that stocks are not lottery tickets.” – Peter Lynch
“Learn everyday, but especially from the experiences of others. It’s cheaper!” – John Bogle
“When purchasing depressed stock in troubled companies, seek out the ones with the superior financial positions and avoid the ones with loads of bank debt.” – Peter Lynch
“No stock price is too low for bears or too high for bulls.” – John F. Heerdink, Jr.
“Investment is most successful when it is most businesslike.” – Ben Graham
“Value stocks are about as exciting as watching grass grow, but have you ever noticed just how much your grass grows in a week?” – Christopher Browne
“Even the intelligent investor is likely to need considerable willpower to keep from following the crowd.” – Benjamin Graham
“Individual who cannot master their emotions are ill-suited to profit from the investment process.” – Benjamin Graham
“I made my first investment at age eleven. I was wasting my life until then.” – Warren Buffet
“I don’t look to jump over seven-foot bars; I look around for one-foot bars that I can step over.” — Warren Buffett
“There are only three measurements that tell you nearly everything you need to know about your organization’s overall performance: employee engagement, customer satisfaction, and cash flow. It goes without saying that no company, small or large, can win over the long run without energized employees who believe in the mission and understand how to achieve it.” – Jack Welch, former CEO of GE
“Opportunities come infrequently. When it rains gold, put out the bucket, not the thimble” ― Warren Buffett
“If you buy things you do not need, soon you will have to sell things you need.” – Warren Buffet
“How many millionaires do you know who have become wealthy by investing in savings accounts? I rest my case.” — Robert G. Allen
“It’s far better to buy a wonderful company at a fair price, than a fair company at a wonderful price.” – Warren Buffett
“A market downturn doesn’t bother us. It is an opportunity to increase our ownership of great companies with great management at good prices.” — Warren Buffett
“Every once in a while, the market does something so stupid it takes your breath away.” — Jim Cramer
“The person who starts simply with the idea of getting rich won’t succeed; you must have a larger ambition.” — John D. Rockefeller
“Know what you own, and know why you own it.” – Peter Lynch
“Although it’s easy to forget sometimes, a share is not a lottery ticket… it’s part ownership of a business.” – Peter Lynch
“Wise spending is part of wise investing. And it’s never too late to start.” – Rhonda Katz
“Invest for the long haul. Don’t get too greedy and don’t get too scared.” – Shelby M.C. Davis
“Fear incites human action far more urgently than does the impressive weight of historical evidence.”
-Jeremy Siegel
“With a good perspective on history, we can have a better understanding of the past and present, and thus a clear vision of the future.” — Carlos Slim Helu
“If we like a business, we’re going to buy as much of it as we can and keep it as long as we can. And when we change our mind, we don’t take half measures.” – Warren Buffett
“The most contrarian thing of all is not to oppose the crowd but to think for yourself.” — Peter Thiel
“Never depend on a single income, make an investment to create a second source.” Warren Buffet“Games are won by players who focus on the playing field –- not by those whose eyes are glued to the scoreboard.” ― Warren Buffett
“The key to making money in stocks is not to get scared out of them.” – Peter Lynch
“Courage taught me no matter how bad a crisis gets … any sound investment will eventually pay off.” — Carlos Slim Helu
“Investing puts money to work. The only reason to save money is to invest it.” – Grant Cardone
“As time goes on, I get more and more convinced that the right method of investment is to put fairly large sums into enterprises which one thinks one knows something about and in the management of which one thoroughly believes.” — John Maynard Keynes
“Given a 10% chance of a 100 times payoff, you should take that bet every time.” — Jeff Bezos
“Money is always eager and ready to work for anyone who is ready to employ it.” ― Idowu Koyenikan
“The secret to investing is to figure out the value of something – and then pay a lot less.” – Joel Greenblatt
“We don’t have an analytical advantage, we just look in the right place.” – Seth Klarman
“Men, it has been well said, think in herds. It will be seen that they go mad in herds, while they only recover their senses slowly, and one by one.” – Charles Mackay
“It’s not whether you’re right or wrong that’s important, but how much money you make when you’re right and how much you lose when you’re wrong.” – George Soros
“In investing, what is comfortable is rarely profitable.” — Robert Arnott
“Don’t look for the needle in the haystack. Just buy the haystack!” — John Bogle
“No Price is too low for a bear or too high for a bull.” — Anonymous
“Investment is an asset or item that is purchased with the hope that it will generate income or appreciate in the future.” — Anonymous
“Behind every stock is a company. Find out what it’s doing.” — Peter Lynch
“Wise spending is part of wise investing. And it’s never too late to start.” –Rhonda Katz
“If there is one common theme to the vast range of the world’s financial crises, it is that excessive debt accumulation, whether by the government, banks, corporations, or consumers, often poses greater systemic risks than it seems during a boom.” — Carmen Reinhart
“It amazes me how people are often more willing to act based on little or no data than to use data that is a challenge to assemble.” ― Robert Shiller
“A bull market is like sex. It feels best just before it ends.” — Barton Biggs
“The investor’s chief problem — even his worst enemy — is likely to be himself.” — Benjamin Graham
“No profession requires more hard work, intelligence, patience, and mental discipline than successful speculation.” – Robert Rhea
“The most contrarian thing of all is not to oppose the crowd but to think for yourself.” — Peter Thiel
“Money is like a sixth sense – and you can’t make use of the other five without it.” – William Somerset Maugham
“Compound interest is the eighth wonder of the world. He who understands it, earns it. He who doesn’t, pays it.” — Albert Einstein
“The stock market is a device for transferring money from the impatient to the patient.” – Warren Buffett
“Thousands of experts study overbought indicators, head-and-shoulder patterns, put-call ratios, the Fed’s policy on money supply…and they can’t predict markets with any useful consistency, any more than the gizzard squeezers could tell the Roman emperors when the Huns would attack.” – Peter Lynch
“Investing puts money to work. The only reason to save money is to invest it.” – Grant Cardone
“Formal education will make you a living; self-education will make you a fortune.” – Jim Rohn
“You cannot save time for your future use however you can invest time for your future.” – John F. Heerdink, Jr.
“We always live in an uncertain world. What is certain is that the United States will go forward over time.” – Warren Buffett
“Never test the depth of the river with both of your feet.” – Warren Buffet
“Know what you own, and know why you own it.” – Peter Lynch
“Liquidity is only there when you don’t need it.” -Old Proverb
“There is no such thing as no risk. There’s only this choice of what to risk, and when to risk it.” – Nick Murray
“If you want to be a millionaire, start with a billion dollars and launch a new airline.” – Richard Branson
“Fear incites human action far more urgently than does the impressive weight of historical evidence.” – Jeremy Siegel
“In investing, what is comfortable is rarely profitable.” – Robert Arnott
“Spend each day trying to be a little wiser than you were when you woke up.” – Charlie Munger
“The entrance strategy is actually more important than the exit strategy.” – Edward Lampert
“The rivers don’t drink their own water; Trees don’t eat their own fruits. The sun does not shine for itself, And flowers do not spread their fragrance For themselves. Living for others is a rule of nature” – PopeFrancis
“It is impossible to produce superior performance unless you do something different from the majority.” – John Templeton
“Inaction and patience are almost always the wisest options for investors in the stock market.” – Guy Spier
“Remember that the stock market is a manic depressive.” – Warren Buffett
“An investment in knowledge pays the best interest.” – Benjamin Franklin
“I believe the returns on investment in the poor are just as exciting as successes achieved in the business arena, and they are even more meaningful!” -Bill Gates
“Every portfolio benefits from bonds; they provide a cushion when the stock market hits a rough patch. But avoiding stocks completely could mean your investment won’t grow any faster than the rate of inflation.” – Suze Orman
“The tax on capital gains directly affects investment decisions, the mobility and flow of risk capital… the ease or difficulty experienced by new ventures in obtaining capital, and thereby the strength and potential for growth in the economy.” – John F. Kennedy
“If all the economists were laid end to end, they’d never reach a conclusion.
-George Bernard Shaw
“The riskiest thing we can do is just maintain the status quo. I get up at 4:30 in the morning, seven days a week, no matter where I am in the world. I think it is important for people who are given leadership roles to assume that role immediately. What I’ve really learned over time is that optimism is a very, very important part of leadership.” – Bob Iger, Former Ceo of Disney
“In the short run, the market is a voting machine. But in the long run, it is a weighing machine.” – Ben Graham
“In investing, what is comfortable is rarely profitable.” -Robert Arnott
“The fundamental law of investing is the uncertainty of the future.” -Peter Bernstein
“How many millionaires do you know who have become wealthy by investing in savings accounts?” -Robert G Allen
“Greed is all right, by the way. I think greed is healthy. You can be greedy and still feel good about yourself.”-Ivan Boesky
“Michael Marcus taught me one other thing that is absolutely critical: You have to be willing to make mistakes regularly; there is nothing wrong with it. Michael taught me about making your best judgment, being wrong, making your next best judgment, being wrong, making your third best judgment, and then doubling your money.” -Bruce Kovner
“The policy of being too cautious is the greatest risk of all.” -Jawaharlal Nehru
“I talk about macro themes a lot because they are fun to talk about, but it is the risk management that is the most important thing. The risk control is all bottom-up. I structured the business right from the get-go so that we would have lots of diversification.” -Michael Platt
“Blaming speculators as a response to financial crisis goes back at least to the Greeks. It’s almost always the wrong response.” -Larry Summers